CCR8 antibody LM-108 submitted US FDA clinical study application in December 2021. This study is a multi-center clinical study designed to evaluate the safety and initial efficacy of LM-108.
Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.
